RxDoctor Payments Data

Michael Driscoll, DO

Pulmonary Disease · Cherry Hill, NJNPI 1497946792

Payments from drug & device makers

$9,575in general payments, 2019–2025

Across 501 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$536
  • Jazz Pharmaceuticals Inc.$508
  • Sanofi$462
  • Boehringer Ingelheim$437
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$2773%
  • Food & beverage$9,21196%
  • Education$861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,575 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$220,523
Medicare patients
787
Services billed
1,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter207$165,968
Dupixent PenDupilumab31$121,555
Breo ElliptaFluticasone/Vilanterol205$88,153
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$35,108
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$31,304
EliquisApixaban16$16,982
Spiriva RespimatTiotropium Bromide19$14,277
Tiotropium Bromide11$11,180
Albuterol Sulfate HfaAlbuterol Sulfate250$9,771
Arnuity ElliptaFluticasone Furoate28$6,175
Qvar RedihalerBeclomethasone Dipropionate17$5,597
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$5,314
Fluticasone-SalmeterolFluticasone Propion/Salmeterol56$5,229
DuleraMometasone/Formoterol16$4,431
SymbicortBudesonide/Formoterol Fumarate20$4,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,067$291,600484 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,506$39,30463 claims
Boehringer IngelheimSpiriva Respimat$437$14,27719 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$14$5,59717 claims
MerckDulera$104$4,43116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →